Clinical Trials Directory

Trials / Unknown

UnknownNCT01427127

Effect of Ramosetron on Bowel Motility After Colorectal Resection

Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
64 (estimated)
Sponsor
Kyunghee University Medical Center · Academic / Other
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Ramosetron is effective in preventing postoperative nausea and vomiting. Several studies reported that ramosetron is also effective treatment diarrhea-predominant irritable bowel syndrome. The investigators examine the effect of ramosetron used for preventing postoperative nausea and vomiting on bowel motility.

Detailed description

Ramosetron, a new potent and long-acting selective 5-HT3 receptor antagonist, is effective for preventing postoperative nausea and vomiting. Also several studies reported that ramosetron is effective treatment of irritable bowel syndrome because it inhibits the accelerated colonic transit, abnormal colonic water transport, defecation abnormality, and the lowered colonic perceptual threshold by corticotrophin-releasing hormone. There is no study about the effect of ramosetron used for preventing postoperative nausea and vomiting on postoperative bowel motility. In this study, the investigators examine the effect of ramosetron on postoperative bowel motility.

Conditions

Interventions

TypeNameDescription
DRUGRamosetronPatients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.

Timeline

Start date
2010-12-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2011-09-01
Last updated
2011-09-01

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01427127. Inclusion in this directory is not an endorsement.